Literature DB >> 31186864

Assessment and management of comorbidities (including cardiovascular disease) in patients with nonalcoholic fatty liver disease.

Kathleen E Corey1,2, Raj Vuppalanchi3.   

Abstract

Entities:  

Year:  2012        PMID： 31186864      PMCID： PMC6499273          DOI： 10.1002/cld.26

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  7 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader; Gianfranco Pagano
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

3.  Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.

Authors:  Dawn M Torres; Frances J Jones; Janet C Shaw; Christopher D Williams; John A Ward; Stephen A Harrison
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

4.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  N Engl J Med       Date:  2010-04-28       Impact factor: 91.245

5.  The Framingham risk score and heart disease in nonalcoholic fatty liver disease.

Authors:  Sombat Treeprasertsuk; Scott Leverage; Leon A Adams; Keith D Lindor; Jennifer St Sauver; Paul Angulo
Journal:  Liver Int       Date:  2012-02-02       Impact factor: 5.828

6.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

Review 7.  Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.

Authors:  Raj Vuppalanchi; Naga Chalasani
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425
  7 in total
  1 in total

1.  Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia.

Authors:  Igor V Maev; Aleksey A Samsonov; Liudmila K Palgova; Chavdar S Pavlov; Elena Shirokova; Kirill M Starostin
Journal:  BMJ Open Gastroenterol       Date:  2019-08-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.